Back to search

Democritus University of Thrace (DUTH)

Η μελέτη της επίδρασης του ανταγωνιστή της αλδοστερόνης, επλερενόνη, στην πρόγνωση ασθενών μετά από οξύ έμφραγμα του μυοκαρδίου και διατηρημένη συστολική λειτουργία της αριστεράς κοιλίας, με κριτήριο τον προσδιορισμό των επιπέδων ορού της μεταλλοπρωτεϊνάσης-9

Abstract

dc:description

Objectives We sought to assess possible interactions between eplerenone use and a plasma marker of collagen turnover on prognosis in post-myocardial infarction (MI) patients with preserved left ventricular (LV) ejection fraction (≥40%).Background In post-MI patients with systolic LV dysfunction eplerenone may improve survival. The beneficial effect of eplerenone on prognosis may be mediated through eplerenone’s effect on cardiac fibrosis. Methods 303 patients with acute MI (58±11 years, 249 male) and preserved systolic LV function were studied prospectively for 24 months. Plasma levels of matrix metalloproteinase-9 (MMP-9) were assessed on 7th day post-MI. Patients were divided into groups according to whether (n=201) or not (n=102) they received eplerenone (25 mg daily) as well as to their baseline MMP-9 levels using as a cut-off the one suggested by ROC curve analysis (12.7 ng/mL). The combination of death from cardiovascular causes, new non-fatal recurrent MI, hospitalisation for unstable angina and development of heart failure symptoms were considered as study end-points. Results Event-free survival was significantly lower among patients with low baseline MMP-9 levels compared to high baseline levels (56% vs. 76%, p<0.001). Eplerenone use was not associated with better prognosis in the whole study group (p=0.132). A beneficial eplerenone effect on outcome was significant only in patients with low baseline levels of MMP-9 (eplerenone (n=69): 65% vs. non eplerenone arm (n=33) 35%, p=0.005) Eplerenone had no effect (p=0.741) in the subgroup of patients with high MMP-9 baseline levels. Conclusions In post-MI patients with preserved LV systolic function, low baseline levels of MMP-9 are significantly associated with poor outcome and also identify a sub-group of patients in whom eplerenone use is associated with a survival benefit.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kampouridis, Nikolaos
  • Καμπουρίδης, Νικόλαος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/34918

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kampouridis, Nikolaos; Καμπουρίδης, Νικόλαος. Η μελέτη της επίδρασης του ανταγωνιστή της αλδοστερόνης, επλερενόνη, στην πρόγνωση ασθενών μετά από οξύ έμφραγμα του μυοκαρδίου και διατηρημένη συστολική λειτουργία της αριστεράς κοιλίας, με κριτήριο τον προσδιορισμό των επιπέδων ορού της μεταλλοπρωτεϊνάσης-9. Democritus University of Thrace (DUTH), 2014. http://hdl.handle.net/10442/hedi/34918